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1. Introduction 
Neither the biological basis of depression (Nemeroff & Vale, 2005; Kasper & McEwen, 
2008) nor the precise mechanism of antidepressant efficacy are completely understood 
(Dudra-Jastrzebska et al., 2007). Indeed, antidepressants are widely prescribed for 
anxiety and disorders other than depression. For example, they are the drug therapy of 
choice for severe anxiety disorders such as agoraphobia, generalized anxiety disorder, 
social phobia, obsessive-compulsive disorder and post-traumatic stress disorder 
(Baldessarini, 2001). Antidepressants are also employed as a therapeutic tool in disorders 
such as drug addition (e.g. Schatzberg, 2000), enuresis (e.g. Humphreys & Reinberg, 
2005) and chronic pain (e.g. Sindrup et al., 2005). This wide application of the effects of 
antidepressants and the heterogeneity of their mechanism of action suggest the existence 
of a common therapeutic mechanism among the disorders which these drugs are 
employed to treat. 
A series of studies have associated major depression with significant atrophy within the 
hippocampus (Campbell et al., 2004; Paizanis et al., 2007). If the hippocampus plays a 
central role in learning and memory, alterations in this structure could well be related to the 
cognitive deficits observed during depressive episodes (Paizanis et al., 2007; Sahay & Hen, 
2007). The cognitive impact of antidepressants (Amado-Boccara et al., 1995) and the 
association between depression and memory impairment (Castaneda et al., 2008) are better 
understood in the framework of an emerging hypothesis that suggests that the pathogenesis 
and treatment of depression are involved in the plasticity of neuronal pathways (Pittenger & 
Duman, 2008; Vaidya & Duman, 2001). This plasticity would seem to modify the strength of 
synapses in the neural pathway involved in depression. 
Given that the strength of synapses is key to the neurobiology of memory (Hebb, 1949; Morris 
et al., 2003), it was proposed some years ago that memory impairment - understanding 
memory as the trace left in the nervous system not only by individual experiences but also by 
genetic and epigenetic phenomena - is central to the therapeutic action of antidepressants and 
other psychotropic medications (Parra, 2003). This idea is complementary to the concept that 
depression circuits learn to malfunction and retain the memory of said malfunctioning (Parra, 
2003). A similar vision of the relationship between learning, memory and depression was 
upheld in a later publication by Stahl (2008), who argued that, in depression, neural circuits 
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learn to become inefficient in a process so called “diabolical learning” (p. 229). In this context, 
antidepressants would modify this memory trace through a process of neural plasticity. 
Moreover, due to evolutionary economy, there would be similarities among the molecular 
changes induced by different causes of neural plasticity, including chronic treatment with 
antidepressants (Duman et al., 1999) or antipsychotics (Konradi & Heckers, 2001), long-term 
sensitization of the gill-withdrawal reflex of aplysia (Kandel, 2001), and delayed neural death 
after ischemic insult (Tsukahara et al., 1998). The similarities among these causes were 
discussed in a review by Parra (2003; in particular Fig. 1). 
Different neurotransmission systems have been implicated in high brain functions such as 
learning and memory (Myhrer, 2003). Some of them are implicated in the mechanism of 
action of antidepressant drugs and could be responsible for the memory deficits observed 
with these drugs: the cholinergic system (Everitt & Robbins, 1997), the serotonergic system 
(Bert et al., 2008), the noradrenergic system (Hertz et al., 2004) and the histaminergic system 
(Passani et al., 2000). The effects of antidepressants on memory in animals may be 
attributable to a combination of their neuropharmacological properties, including 
anticholinergic, antihistaminergic, serotonergic and noradrenergic activity (Monleón et al., 
2008).  
We have previously reviewed studies of the effects of antidepressants on animal memory 
(Monleón et al., 2008). These studies provide several valuable insights into the effects of 
antidepressants on memory:  
1. The memory impairment produced by several antidepressants is not confined to those 
with anticholinergic properties. 
2. Although there are relatively few studies involving chronic antidepressant administration, 
they reveal an absence of tolerance, which is present regardless of the mechanism 
responsible for the therapeutic effects of antidepressants. This lack of tolerance suggests 
that the influence of antidepressants on memory is related to their therapeutic effects.  
3. When the effects of antidepressants are assessed, in addition to their effects on mood 
and anxiety, those on cognitive processes, such as learning and memory, should also be 
considered. 
4. The plethora of studies performed with aversive stimuli is understandable given the 
negative nature of depression. However, the scarcity of studies involving female 
subjects is less comprehensible and indeed inexcusable given that the incidence of 
depression is much higher among women than men. 
A series of experiments on the effects of different antidepressants on memory in mice have 
been carried out in our laboratory. These experiments have already been previously, or will 
be published. Specifically these experiments were programmed to study: 
 The effects of acute and chronic administration of several antidepressants 
(amitriptyline, maprotiline and fluoxetine) on inhibitory avoidance (IA) learning. 
 The effects of antidepressants on learning and memory, dissociating them from those 
on activity, anxiety and analgesia, which can interfere with the performance of the IA 
response. 
 The potential state-dependent learning (SDL) of antidepressants in the IA task. SDL is a 
useful behavioural model to explain the influence of drugs on memory, and more 
specifically for the study of memory-retrieval mechanisms (Arkhipov, 1999). 
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 The neurochemical substrates of IA learning in association with the neurochemical 
substrates of antidepressants. The cholinergic, histaminergic and serotonergic systems 
are involved in IA learning, and the effects of antidepressants on these systems can 
modulate the learning of this task. 
 The possible sex differences in these effects of antidepressants. 
An in-depth review of this body of work is presented herein. We will summarize and 
discuss the effects of the antidepressants amitriptyline, maprotiline and fluoxetine on an IA 
task in male and female mice, with reference to specific memory processes such as 
acquisition, consolidation and retrieval. 
2. Behavioural procedures: Inhibitory avoidance learning and complementary 
tests 
2.1 Inhibitory avoidance learning 
Inhibitory avoidance (also called passive avoidance) is one of the most common procedures 
for evaluating memory in animals (e.g. Gold, 1986; Heise, 1981), as this task is learned in a 
single trial, which facilitates the timing of drug administration. This is crucial in 
discriminating the effects of a drug on different memory processes, such as acquisition, 
consolidation or retrieval (for a review of the usefulness of the IA procedure in memory 
studies, see Izquierdo & McGaugh, 2000).  
The step-through version of IA conditioning was used in the experiments reviewed here 
(see Figure 1). The IA apparatus (Ugo Basile, Comerio-Varese, Italy), which was placed 
within an isolation box, consisted of a cage made of Perspex sheets and divided into two 
compartments (both  15 cm high x 9.5 cm wide x 16.5 cm long). The chambers are 
separated widthwise by a flat-box partition with an automatically-operated sliding door 
at floor level. The floor is made of stainless steel bars of 0.7 mm in diameter and situated 8 
mm apart. The starting compartment is white and continuously illuminated by a light 
fixture fastened to the cage lid (24 V, 10 W, light intensity of 290 lux at floor level, 
measured with the Panlux Electronic2 photometer, manufactured by GOSSEN, Nürnberg, 
Germany), whereas the “shock” compartment is comprised of black Perspex panels and is 
kept in darkness at all times. 
The procedure was completed in two phases: training and test.  
 Training began with a 90 sec period of adaptation to the light compartment before the 
door to the other compartment was opened. This door was then opened for a maximum 
of 300 sec, and if the animal entered the dark compartment it received an inescapable 
footshock of 0.3-0.7 mA that was delivered for 5-10 sec (0.3 mA and 5 sec were the more 
frequently used values). 
 During the test, mice were placed once again in the light compartment of the apparatus 
and the procedure used in the training phase was repeated, but without the shock. The 
time taken to enter the dark compartment, defined as latency, was automatically 
measured in tenths of a second and recorded manually at the end of each phase. 
Crossing latencies longer than 300 sec in the test phase resulted in the trial being 
terminated and a latency of 300 sec recorded. 
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Fig. 1. Inhibitory avoidance apparatus. A step-through version of inhibitory avoidance 
conditioning for mice, placed inside an isolation box. The two compartments are separated 
widthwise by a flat-box partition. 
Tests were always carried out during the dark phase of the light/dark cycle, after 7-10 days 
of acclimatization to the animal facility. The training-test interval was 24 hours, or 4, 7 or 21 
days (according to the drug administered and the administration schedule). Latencies that 
were longer in the test than in the training phase were considered IA. 
2.2 Complementary tests 
The effects of antidepressants on locomotor activity (e.g. Mitchell et al., 2006), anxiety (e.g. 
Hascoët et al., 2000) and analgesia (e.g. Duric & McCarson, 2006) can interfere with the 
performance of subjects in the IA task (McGaugh & Izquierdo, 2000). Thus, it was 
important for the purpose of this investigation to dissociate the effects of the drugs on 
learning and memory from those on activity, anxiety and analgesia (McGaugh, 1989). In 
order to clarify the effects of antidepressants on IA learning, the following complementary 
tests were used:  
 Two actimeters. In one of the actimeters (ACTIMET from Cibertec S.A., Madrid, 
Spain) the horizontal activity was measured using an infrared photocell system. The 
photocell line was located 2.5 cm above the floor. Each photocell box measured 8.5 x 
17 x 35 cm and had sixteen photocells located along its long side (see Figure 2). The 
animals’ behaviour was continuously recorded and accumulated every minute for 
five minutes. 
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Fig. 2. Complementary tests: Actimeter. This apparatus registers the spontaneous locomotor 
activity of the animals by means of an infrared photocell system. 
The second actimeter (Actisystem II with ‘DAS 16’ software from Panlab S.L., 
Barcelona, Spain) registered the spontaneous locomotor activity as a function of the 
variations produced by mouse' movements on the standard frequency (484 kHz) of the 
electromagnetic field of the sensory unit (35 x 35 cm2). Frequency variations were 
transformed into voltage changes, which, in turn, were converted into impulses that 
were collected by a counter when they reached a certain level (see Figure 3). The 
locomotor activity of the animals was monitored for five minutes. 
 
Fig. 3. Complementary tests: Sensor unit of the actimeter. This unit registers the variations of 
the oscillation frequency in the electromagnetic field produced by the mouse' movements. 
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 An elevated plus-maze (Cibertec S.A., Madrid, Spain) (see Figure 4). This maze 
consisted of two open arms (30 x 5 cm2 each) and two closed arms (30 x 15 x 5 cm3 each) 
which all fed into a common central square (5 x 5 cm2). The maze was made of Plexiglas 
(black floor and walls) and was elevated 45 cm above the floor level. Sessions lasted 5 
min and began with the subject being placed in an open arm (facing the central square). 
All sessions were videotaped with a standard VHS system for subsequent analysis. The 
maze was cleaned after each subject. The number of entries into open and closed arms 
(arm entry is defined as all four paws entering an arm) was scored by a trained observer 
who was unaware of the treatment applied. This provided a measurement of anxiety, 
the percentage of open arm entries [(open/open + closed) X 100], and a measurement of 
activity (number of closed arm entries). These measurements were based on former 
studies: File (2001), Lister (1987), and Rodgers & Johnson (1995). 
 
Fig. 4. Complementary tests: Elevated plus-maze for mice. This test measures anxiety and 
activity. 
 A prototype of analgesia (Cibertec S.A., Madrid, Spain) (see Figure 5). This apparatus 
consisted of a translucent Perspex box of the same dimensions as those of one side of 
the avoidance apparatus, with a similar floor to the IA apparatus and a constant current 
source with increasing output steps of 0.059 mA. Subjects were individually introduced 
into the test box and allowed a 2 min adaptation period. Subsequently, the animal 
received a 5 sec shock of 0.059 mA, increasing proportionately by 0.059 mA every 10 
sec. The test was interrupted when the subject removed all four paws from the grid for 
the first time during the shock (this was done while the test was underway; and is a 
different criterion to that of jump threshold, which was determined on viewing the 
recorded sessions). The highest shock delivered was 0.77 mA. Results were represented 
as flinch and jump thresholds in milliamperes. Flinch threshold was defined as the 
lowest shock level that elicited a detectable response, and jump threshold as the lowest 
shock level that elicited simultaneous removal of three paws from the grid. All tests 
were videotaped with a standard VHS system and later assessed. 
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Fig. 5. Complementary tests: Prototype of analgesia. This test measures flinch and jump 
thresholds. 
 A Morris water maze (Cibertec S.A., Madrid, Spain) (see Figure 6). This test was 
employed in order to evaluate the effects of maprotiline on spatial learning. The maze 
consisted of a circular pool made of black Plexiglas (1 m diameter and 30 cm high), 
based on that described by Morris (1984) but adapted for mice (Lamberty & Gower, 
1990). The maze was filled with water to a depth of 15 cm and maintained at 24  1 ºC. 
A small platform (6 x 6 cm) was submerged 1 cm below the surface of the water in the 
target quadrant. Several extramaze cues, including laboratory equipment and posters, 
were available around the pool. During the acquisition phase mice performed 4 trials 
per day for 4 consecutive days. After an inter-trial interval of 30 sec the trial began by 
placing the mouse on the platform for 30 sec. Mice were then placed in the water with 
their noses pointing towards the wall at one of the three starting points in a random 
manner. During this phase animals were allowed 60 sec to find the hidden platform. If 
unable to do so, they were led to it by the experimenter. Animals were allowed to stay 
on the platform for 30 sec, regardless of whether they had found it independently or 
after guidance. Starting positions were chosen at random from the three possible sites 
around the pool’s perimeter, which were situated in each of the quadrants not occupied 
by the platform. The starting positions were determined so that two successive trials 
never began from the same position. In a retention phase (probe trial) carried out on the 
fifth day the platform was removed and mice were allowed to swim for 100 sec after 
starting in the opposite quadrant to that in which was the platform during acquisition. 
A video-camera recorded the probe trials. The measures obtained were escape latency 
(time to reach the submerged platform) during the acquisition trials and search time in 
each quadrant during the probe trial. The drug was administered 30 min before each 
experimental session. The use of this test was occasional in our research and 
complementary to the IA learning. 
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Fig. 6. Morris water maze for mice. This test evaluates spatial learning. 
3. Antidepressant and complementary drugs 
The following antidepressant drugs were used in these experiments: 
 Amitriptyline hydrochloride (Sigma-Aldrich Química, Madrid, Spain). This tricyclic 
antidepressant is a mixed serotonergic and noradrenergic uptake inhibitor with a strong 
anticholinergic and antihistaminergic effect (Richelson, 2003). Amitriptyline is one of 
the most-studied antidepressants with regard to effects on cognitive functions, 
including memory and tends to be the standard against which newer compounds are 
compared (Thompson, 1991). Among currently available antidepressants, amitriptyline 
is the most potent in blocking muscarinic cholinergic receptors (Frazer, 1997; Owens et 
al., 1997, Richelson, 2001; Stahl, 1998). The effects of acute administration of 
amitriptyline on IA were evaluated at doses of 2.5, 5, 7.5, 10, 15, 20 and 30 mg/kg. 
Chronic administration of the highest dose was also evaluated. 
 Maprotiline hydrochloride (Ciba-Geigy A.G., Basel, Switzerland). This is a tetracyclic 
antidepressant prescribed largely for the elderly (Gareri et al., 2000). It selectively inhibits 
norepinephrine reuptake and has a high antihistaminergic activity, a modest 
anticholinergic activity and a low serotonin reuptake inhibitory effect (Gareri et al., 2000; 
Harvey et al., 2000; Pinder et al., 1977; Redrobe & Bourin, 1997; Richelson & Nelson, 1984). 
This compound has fewer side effects than classic tricyclic antidepressants (Grüter & 
Pöldinger, 1982), but what it does have in common is the impairment of memory (Gareri 
et al., 2000). The effects of acute administration of Maprotiline on IA were evaluated at 
doses of 2.5, 5, 10, 15, 20 and 25 mg/kg. The 5, 10 and 20 mg/kg doses were also 
evaluated after chronic administration and the effects of the 15, 20 and 25 mg/kg doses on 
spatial learning were evaluated after subchronic administration. 
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 Fluoxetine hydrochloride (Eli Lilly, Indianapolis, U.S.A.). This is a selective serotonin 
reuptake inhibitor with little affinity for muscarinic, histaminic H1, serotonergic 5-HT1 
or 5-HT2, or noradrenergic alpha 1 or alpha 2 receptors (Beasley et al., 1992; Stark et al., 
1985). The effects of acute administration of fluoxetine on IA were evaluated at doses of 
5, 10, 15 and 20 mg/kg. Chronic administration of the highest dose was also analysed. 
The following complementary drugs were also used in some of the experiments: 
 Piracetam (Sigma-Aldrich Química, Madrid, Spain), whose mechanism of action is still 
unclear but which appears to be a non-specific activator of neuronal excitability 
(Gouliaev & Senning, 1994). A 100 mg/kg dose of piracetam was evaluated in the IA 
procedure after both acute and chronic administration and in combination with 
amitriptyline (100 mg/kg dose of piracetam and 30 mg/kg of amitriptyline). 
 Oxotremorine sesquifumarate (Sigma-Aldrich Química, Madrid, Spain), a centrally 
acting muscarinic cholinergic agonist (Introini-Collison & Baratti, 1992). The effects of 
acute administration of oxotremorine on IA were evaluated at doses of 0.05 and 0.1 
mg/kg and in combination with amitriptyline (0.05 mg/kg dose of oxotremorine and 5, 
10 or 15 mg/kg of amitriptyline; 0.1 mg/kg dose of oxotremorine and 5, 7.5 or 10 
mg/kg of amitriptyline). 
 Physostigmine salicylate (Sigma-Aldrich Química, Madrid, Spain), a centrally acting 
anticholinesterase (Boccia et al., 2003). The effects of acute administration of 
physostigmine on IA were evaluated at doses of 0.15, 0.3 and 0.6 mg/kg, and each of 
these doses were also combined with 5 mg/kg of amitriptyline. 
 L-Histidine monohydrochloride monohydrate (Sigma–Aldrich Química, Madrid, 
Spain), a precursor of histamine (Prell et al., 1996), was evaluated in the IA procedure, 
given alone (250, 500 and 1000 mg/kg) and in combination with amitriptyline (1000 
mg/kg of l-histidine and 2.5 or 10 mg/kg of amitriptyline). 
 Pyrilamine maleate (Sigma–Aldrich Química, Madrid, Spain), a histamine H1 
postsynaptic receptor antagonist (Yanai et al., 1990), was administered alone (5, 10 and 
20 mg/kg) and with amitriptyline (20 mg/kg of pyrilamine and 2.5, 5, or 10 mg/kg of 
amitriptyline) in order to study their effects on IA. 
All drugs were diluted in physiological saline and intraperitoneally injected at a volume of 
0.01 ml/g body weight. Doses were calculated as the weight of the base. Control groups 
received the same volume of physiological saline. 
4. Results 
4.1 Amitriptyline  
Table 1 summarizes the results and some procedural details of the experiments carried out 
with amitriptyline. They are grouped below in seven categories: 1) Effects of acute 
administration of amitriptyline on IA; 2) Effects of chronic administration of amitriptyline 
on IA; 3) Modulation of the acute and chronic effects of amitriptyline by piracetam; 4) 
Modulation of the acute effects of amitriptyline by the cholinergic system; 5) Modulation of 
the acute effects of amitriptyline by the serotonergic system; 6) Modulation of the acute 
effects of amitriptyline by the histaminergic system; 7) Study of potential state-dependent 
learning. 
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Abbreviations: Tr. = Treatment; SDL = state dependent learning; M = male; F = female; A = Acute 
administration; SC = Subchronic administration (5 days); C = Chronic administration (21 days); 0 = No 
effect;  = impairment; + = improvement; a = memorization deficit; b = memorization deficit and 
performance facilitation. 
Table 1. Effects of different doses of amitriptyline on IA learning, activity, anxiety and SDL 
in mice.  
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1. Effects of acute administration of amitriptyline on memory acquisition/consolidation in 
male OF1 mice (Everss et al., 1999) and CD1 mice of both sexes (Parra et al., 2002). Three 
doses of this tricyclic antidepressant (7.5, 15 and 30 mg/kg) were administered 
immediately after IA training. Subjects were tested for avoidance twenty four hours 
later. Amitriptyline impaired IA consolidation at doses of 7.5, 15 and 30 mg/kg in OF1 
and CD1 males, and at doses of 7.5 and 30 mg/kg in CD1 females. The sex differences 
observed were limited to a slightly stronger effect of amitriptyline on IA in males than 
in females. These results indicate that acute amitriptyline administration produces 
retrograde amnesia in a IA task, which does not seem to be mediated by anxiolytic 
effects:  when CD1 mice explored an elevated plus-maze during a five-minute period 
forty-five minutes after injection amitriptyline had no effect on anxiety (percentage of 
open arm entries) and induced a dose-dependent impairment of activity (number of 
closed arm entries), which did not affect IA, as the drug was administered after training 
(see conclusions regarding  pharmacokinetic rationale). 
Another series of experiments were performed to evaluate the effects of acute pre-
training (5, 7.5, 10, 15, 20 and 30 mg/kg) and post-training (30 mg/kg) administration 
of amitriptyline on IA learning (Urquiza, 2007). Results showed that only acute pre-
training administration produced an impairment of learning. The dose-response 
relationship of the effect of amitriptyline on IA (Parra et al., 2009) was also evaluated at 
doses of 2.5, 5, 10 and 20 mg/kg, which were administered before the training session. 
Results showed a clear dose-dependent impairment of amitriptyline on IA in both male 
and female mice. However, the 2.5 mg/kg dose had no effect on either sex, 5 mg/kg 
had a significant effect only on females, and 10 and 20 mg/kg produced similar 
significant effects in both sexes. A study evaluating changes in the brain metabolism 
induced by training in IA and acute administration of amitriptyline also showed an 
impairing effect of 20 mg/kg of this drug tested in male mice (González-Pardo et al., 
2008). 
2. Effects of 21-day chronic administration of amitriptyline (30 mg/kg) on the acquisition 
and consolidation of an IA task in male and female CD1 mice. It was also investigated 
whether amitriptyline, when administered after consolidation of this task, blocked 
memory retrieval (Parra et al., 2006). Amitriptyline given before the training phase 
blocked learning of IA in males, and a similar tendency was observed in females. 
However, when the drug was administered between training and test phases it did not 
affect conditioning. Anxiety and spontaneous motor activity in the elevated plus maze 
were also assessed in the same subjects, but no effects of amitriptyline were observed. 
Thus, the impairing effects of amitriptyline on IA would seem to be independent of its 
actions on anxiety and locomotor activity. 
3. Modulation of the acute and chronic effects of amitriptyline on IA by piracetam in male 
and female CD1 mice (Everss et al., 2005). The purpose was to study the effects of 
amitriptyline on animal cognition in relation to some characteristics of its therapeutic 
effects. Two experiments were run. In Experiment 1, mice underwent an IA training phase 
sixty minutes after acute piracetam (100 mg/kg) or physiological saline administration. 
Immediately after the behavioural task, they received a single injection of the tricyclic 
antidepressant amitriptyline (30 mg/kg) or physiological saline. Twenty four hours later, 
subjects were tested for avoidance. In Experiment 2, the same doses of amitriptyline and 
piracetam were chronically administered. Mice underwent the IA training phase on the 
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22nd day, and the test phase a further 24 h later. Forty-five minutes after the test, subjects 
were allowed to explore the elevated plus-maze for five minutes in order to assess 
whether the effects of amitriptyline on avoidance performance reflected general 
behavioural changes. The following results were obtained:  
a. Acute and chronic amitriptyline impaired IA in male and female mice. 
b. Piracetam counteracted the effect of acutely administered amitriptyline on IA. 
c. Piracetam counteracted the effects of chronically administered amitriptyline in 
males but not in females in the same learning task. These effects did not seem to be 
mediated by non-specific drug effects on spontaneous motor activity or anxiety. 
4. Modulation of the acute effects of amitriptyline on IA by the cholinergic system in male 
and female CD1 mice (Monleón et al., 2009; Urquiza, 2007). The amnesic effect 
produced by amitriptyline (5, 10 or 15 mg/kg) was not completely counteracted by the 
agonist cholinergic oxotremorine (0.05, 0.1 mg/kg), but a tendency in that direction was 
observed. However the amnesic effect produced by 5 mg/kg of amitriptyline was 
counteracted by several doses of the agonist cholinergic physostigmine (0.15, 0.3 and 0.6 
mg/kg). In this way, physostigmine counteracted the impairing effects of amitriptyline 
on IA to a greater degree than oxotremorine. These differences in the effects of the two 
cholinergic agonists could be due to them possessing different mechanisms of action. 
Oxotremorine is a ligand present at all five of the muscarinic receptor subtypes (Choi et 
al., 1973), while physostigmine is a potent cholinesterase inhibitor (Taylor, 2001) that 
enhances the levels of acetylcholine, which eventually interacts with both the 
muscarinic and nicotinic receptor subtypes. These results demonstrate that the IA 
impairment produced by amitriptyline in both male and female mice is mediated, at 
least partially, by the cholinergic system. 
5. Modulation of the acute effects of amitriptyline on IA by the serotonergic system in 
male and female CD1 mice (Parra et al., 2010). A combination of 2.5 mg/kg of 
amitriptyline with fluoxetine (10, 15 or 20 mg/kg), a selective serotonin reuptake 
inhibitor, revealed that the joint administration of amitriptyline 2.5 mg/kg and 
fluoxetine 15 mg/kg had a clear impairing effect on IA. These results highlight the 
involvement of the serotonergic system in the effects of amitriptyline. 
6. Modulation of the acute effects of amitriptyline on IA by the histaminergic system in 
male and female CD1 mice (Ferrer-Añó, 2008). Amitriptyline (10 mg/kg) produced 
amnesic effects that were not modified in mice treated with this drug and a 
histaminergic precursor, L-histidine (1000 mg/kg), or a H1 antagonist, pyrilamine (20 
mg/kg). L-histidine (250, 500, or 1000 mg/kg) was also administered alone and did not 
produce any effect on IA. No effect was produced by pyrilamine (5, 10, or 20 mg/kg) 
when administered alone. Neither of the two kinds of manipulation of the histamine 
neurotransmitter system (favouring the synthesis of histamine or blocking its action on 
postsynaptic receptors) had an effect on IA. Furthermore, when administered in 
combination with amitriptyline, these drugs did not modify the impairing effect of the 
antidepressant on that memory task. Given that amitriptyline has antihistaminergic 
properties and that the results were not modified by histaminergic manipulation, it 
would appear that the histaminergic system is not involved in the behaviour studied. 
7. Study of potential state-dependent learning. To study the effects of the antidepressants 
on memory we carried out some experiments to investigate whether amitriptyline (30 
mg/kg), maprotiline (25 mg/kg) and fluoxetine (15 mg/kg) produce state-dependent 
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learning (SDL) in the IA task in male and female CD1 mice (Arenas et al., 2006). SDL is 
a phenomenon in which the retrieval of newly acquired information is possible if the 
subject is in the same physiological state as during the encoding phase. Independent 
groups were used for each pharmacological treatment and for each sex using a 2 X 2 
experimental design. The groups were: physiological saline before training and test 
phases (SS); physiological saline before training and amitriptyline before phase test 
(SA); amitriptyline before training and physiological saline before test phase (AS); 
amitriptyline before training and test phases (AA). The interval between phases was of 
24 h. SDL was not detected, and results with amitriptyline can be interpreted as 
representing a memorization deficit (the groups that received a drug before training did 
not show increased test latencies, independently of the treatment administered prior to 
the test session; see Overton, 1974). In addition, males showed a slightly higher 
deterioration in their performance than females. 
4.2 Maprotiline 
Table 2 summarizes the results and some procedural details of the experiments carried out 
with maprotiline. They are grouped below in four categories: 1) Effects of acute and chronic 
administration of maprotiline on IA; 2) Effects of maprotiline on learning, anxiety, activity 
and analgesia; 3) Effects of subchronic administration of maprotiline on spatial learning; 4) 
Study of potential state-dependent learning. 
1. Effects of acute and chronic administration of maprotiline (5, 10 or 20 mg/kg) on IA in 
male OF1 mice (Parra et al., 2000). Acute administration before training did not affect 
training phase latencies but did impair performance in the test at doses of 5 and 20 
mg/kg. When given after training, the drug did not modify test latencies at any of the 
doses used. Chronic administration for 21 days (interrupted 24 h before training) also 
shortened latencies in the test, but not in training. An experiment was performed in 
naive animals to evaluate the acute effects of maprotiline on analgesia at the doses 
stated. No analgesic effect of the drug was observed. Considered as a whole, these 
results indicate that acute maprotiline produces anterograde amnesia, and that 
tolerance does not appear after 21 days of treatment. 
2. Effects of a wide range of doses of maprotiline (2.5, 5, 10, 15, 20 and 25 mg/kg) on 
learning, anxiety, activity and analgesia in male and female CD1 mice (Vinader-Caerols 
et al., 2006). IA learning was complemented with measures of anxiety and locomotor 
activity, which were assessed in the same animals in an elevated plus-maze. A study of 
the acute effects of maprotiline (15, 20 and 25 mg/kg) on analgesia was carried out in 
naive animals of both sexes. Maprotiline impaired IA at doses of 15, 20 and 25 mg/kg. 
The highest dose produced an anxiolytic effect in females, and 20 and 25 mg/kg both 
reduced locomotor activity. Analgesia was observed with the highest dose. The IA 
impairment produced by maprotiline seemed to be independent of the drug’s influence 
on anxiety, was not shadowed by an instrumental performance deficit and, at least in 
the case of the highest dose, appeared to be influenced by the drug’s effects on 
analgesia. It can be hypothesised that acquisition is the memory process principally 
affected by maprotiline, and in particular stimuli processing. The lack of sex differences 
in the effects of maprotiline on IA supports the generalization of data previously 
reported exclusively in males. 
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Abbreviations: Tr. = Treatment; SDL = state dependent learning; M = male; F = female; A = Acute 
administration; SC = Subchronic administration (5 days); C = Chronic administration (21 days); 0 = No 
effect;  = impairment; + = improvement; SL= spatial learning; a = memorization deficit; b = 
memorization deficit and performance facilitation. 
Table 2. Effects of different doses of maprotiline on inhibitory avoidance learning, activity, 
anxiety and SDL in mice. 
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3. Effects of subchronic administration of maprotiline (15, 20 and 25 mg/kg) on spatial 
learning and general activity in male and female CD1 mice in the Morris water maze 
(Vinader-Caerols et al., 2002). In the acquisition phase, maprotiline (15 and 25 mg/kg) 
impaired learning in males but not in females. Sex differences were not found in the control 
group in this phase. In the retention phase, all three doses of maprotiline rectified the sex 
differences observed in the control group. In the general activity test, all three doses of 
maprotiline decreased activity and removed the sex differences found in the control group. 
This sexual dimorphism in the effects of maprotiline on spatial learning is in accordance 
with the findings of studies of the effects of antidepressants and antipsychotics on different 
learning tasks in mice. When this dimorphism is present, the drug effect is observed only in 
males or, if present in males and females, is stronger in the former.  
4. Study of potential SDL with maprotiline (25 mg/kg) following the same procedure as 
that used for amitriptyline (Arenas et al., 2006). The results were interpreted as 
simultaneous memorization deficit and performance facilitation due to motor 
impairment. Similarly to that observed with amitriptyline, males treated with 
maprotiline showed a slightly higher deterioration than females in their performance. 
4.3 Fluoxetine 
Table 3 summarizes the results and some procedural details of the experiments with 
fluoxetine. They are grouped below in three categories: 1) Effects of acute administration of 
fluoxetine on IA; 2) Effects of chronic administration of fluoxetine on IA; 3) Study of 
potential state-dependent learning. 
1. Effects of acute administration of fluoxetine (5, 10 and 20 mg/kg) on memory 
consolidation in male and female OF1 mice (Monleón et al., 2001). The drug was 
administered immediately after the training session and there was a four-day interval 
between sessions. The results confirmed IA learning in all the treatment groups. 
Fluoxetine did not impair memory consolidation in any of the subjects; even the 
animals treated with the highest dose showed significantly increased response latencies 
of IA compared with those treated with the lowest dose or saline. As the drug was 
administered immediately after the training session these results cannot be attributed to 
unspecific effects, which occur when drugs are administered before the training session 
(McGaugh, 1989). Sex differences in this task were observed, with females performing 
better. However, the drug’s effects were not sexually dimorphic: sex differences were 
observed in control animals and they remained with every dose of fluoxetine. Analysis 
of the locomotor activity of the animals did not reveal any significant differences 
between the treatment groups. In another experiment, acute doses of fluoxetine (10, 15 
and 20 mg/kg) were tested in male and female CD1 mice (Parra et al., 2010). The drug 
was administered 30 min before the training phase and the test phase was carried out 
24 h later. Acquisition and consolidation phases of IA not were impaired by fluoxetine. 
In addition, the analysis of fluoxetine revealed that females exhibited longer test 
latencies than males, irrespectively of the pharmacological treatment they had received. 
The very minor sex differences detected in the present study are in accordance with 
existing evidence in the literature which suggest that differences observed in the effects 
of psychotropic medication on the memory of mice are generally stronger among males 
while IA tends to be more pronounced in females.  
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Abbreviations: Tr. = Treatment; SDL = state dependent learning; M = male; F = female; A = Acute 
administration; SC = Subchronic administration (5 days); C = Chronic administration (21 days); 0 = No 
effect;  = impairment; + = improvement; a = memorization deficit; b = memorization deficit and 
performance facilitation. 
Table 3. Effects of different doses of fluoxetine on inhibitory avoidance learning, activity and 
SDL in mice.  
2. Effects of chronic administration of fluoxetine (20 mg/kg) on IA in male and female 
CD1 mice (Monleón et al., 2002). In Experiment 1, the drug was administered for 21 
days before the training session, whereas in Experiment 2, other subjects were subjected 
to the same treatment schedule, only that it began 24 h after the training session. The 
comparison of test versus training latencies revealed a deterioration of memory after 
pre-training administration of fluoxetine (Experiment 1) in males but not females. Sex 
differences in this task were also observed in Experiment 1, with females showing a 
better performance. Sex differences were evident in controls as well as in treated 
animals. The locomotor activity of the animals was also analysed in Experiment 1 and 
showed no statistically significant differences in this measure between treated and non-
treated groups. Due to the absence of sex differences in the effects of fluoxetine on this 
measure, the sex differences observed in the effects of the drug on IA cannot have been 
attributable to non-specific effects on locomotor activity. The lack of an effect of post-
training administration of fluoxetine (Experiment 2) constitutes additional support for 
the idea that the effect on IA observed in Experiment 1 was specifically related to 
learning and memory. In summary, we can affirm that fluoxetine impairs IA in chronic 
pre-training but not in post-training administration. 
3. Study of potential SDL with fluoxetine (15 mg/kg), following the same procedure as 
that employed for amitriptyline and maprotiline (Arenas et al., 2006). Fluoxetine did not 
produce any deteriorating effect on conditioning. 
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5. Conclusions 
In order to construct a global perspective, the results discussed in this review can be 
summarised as follows: 
 In general, acute pre-training administration of amitriptyline and maprotiline impairs 
the acquisition of IA at a wide range of doses, while fluoxetine does not produce any 
effect. 
 Acute post-training administration produces ambiguous results. Amitriptyline can have 
an undermining effect or an absence of effects. Maprotiline does not exert any effects 
and fluoxetine only produces an improvement of memory consolidation at a high dose. 
 Chronic treatment has an effect on pre-training administration of amitriptyline and 
fluoxetine. Males are more affected than females with these antidepressants, with an 
impairment of the acquisition of IA being observed at high doses. Maprotiline, which in 
chronic administration was tested only pre-training, showed a biphasic effect: the 
lowest and the highest doses impair the acquisition of the IA but not the intermediate 
dose. 
 Maprotiline and amitriptyline at high doses reduce locomotor activity. With respect to 
instrumental performance, the decrease in activity observed does not appear to 
influence the performance of animals in the test phase of IA learning, as they cross the 
compartment in less time than controls. This is contrary to what would be expected (i.e., 
that if performance of certain animals is affected, they would show longer test 
latencies). Furthermore, there is a pharmacokinetic reason for ruling out a locomotor 
effect of these drugs in the avoidance test phase, as the interval between injection of the 
drug and the behavioural test was sufficient for the drug to have been eliminated. 
Therefore, the IA impairment produced by maprotiline and amitriptyline is not 
shadowed by their effects on activity. Fluoxetine is the only drug which does not 
produce any effects on locomotor activity. 
 The effects on anxiety were tested with maprotiline and amitriptyline and only the 
highest dose of maprotiline produced an anxiogenic effect in female subjects. The same 
dose of maprotiline also produced an analgesic effect in both male and female mice. The 
effects of this dose on IA learning could be shadowed by its effects on anxiety and 
analgesia, and so this is not a suitable dose to be used in the study of maprotiline and 
IA memory in mice. 
 SDL is a useful behavioural model to explain the influence of drugs on memory, and more 
specifically for the study of memory-retrieval mechanisms (Arkhipov, 1999). SDL is 
employed to refer to behavioural responses learnt while animals are under the influence 
of a centrally acting drug, as thereafter animals perform most efficiently only when the 
same drug condition is re-established (Overton, 1974, 1984). The antidepressants tested 
affect the acquisition/consolidation but not the retrieval process in IA learning. In 
conclusion, our study shows that the effects of the antidepressants amitriptyline, 
maprotiline and fluoxetine are not state-dependent: the drugs’ actions on IA learning 
affect acquisition/consolidation but not the retrieval process. Nevertheless, there are some 
differences between the three antidepressants. Amitriptyline produces a memorization 
deficit in the IA task, while maprotiline exerts a less obvious effect on the consolidation of 
memory due to its interference with motor effects, and fluoxetine has no impairing effects 
on learning. We believe that the differences observed in the effects of these three 
www.intechopen.com
 
Effects of Antidepressants 
 
40
antidepressants on IA memory can be explained by their distinct action on the cholinergic 
system; i.e., the higher the anticholinergic effect, the greater the memory impairment. The 
results reported here were obtained under acute treatment, and therefore should not be 
considered a model of clinical treatment, since antidepressants are chronically 
administered when applied for therapeutic purposes. However, these findings and those 
of similar studies contribute to a better understanding of the effects of antidepressants on 
memory processes, which is crucial for improving their prescription in humans. 
 The neurotransmitters histamine, acetylcholine and serotonin have been related with 
the acquisition and consolidation of memory in IA tasks (Babar et al., 2002; Eidi et al., 
2003). The amnesic effect produced by amitriptyline in our laboratory was not confined 
to the cholinergic system (Monleón et al., 2009; Urquiza, 2007). In fact, the serotonergic 
system was also involved (Parra et al., 2010), as the joint administration of amitriptyline 
and fluoxetine at doses which did not have an effect when given alone had a clear 
impairing effect. We believe this represents a synergistic effect of both drugs, which 
confirms the implication of the serotonergic system in the impairing effects of 
amitriptyline on IA in mice. The histaminergic system does not seem to be implicated in 
this impairing effect of amitriptyline (Ferrer-Añó, 2008).  
 The use of both male and female subjects is especially relevant in animal studies of 
disorders in which sex differences have been described in human beings. In fact, 
epidemiological studies have shown that the lifetime prevalence of major depressive 
disorder in women (21.3%) is almost twice that in men (12.7%), and this ratio has been 
documented in different countries and ethnic groups (Noble, 2005). These sex 
differences have been observed in the prevalence of mental disorders as well as in 
responses to treatment (Frackiewicz et al., 2000). Sex differences in control subjects were 
observed in some experiments carried out in our laboratory, with females exhibiting 
longer latencies than males in the test phase, thus indicating a more effective IA 
learning in females. We have also detected sex differences in the effects of amitriptyline, 
maprotiline and fluoxetine on IA learning. When this dimorphism is present, the drug 
effect is generally stronger in males than in females.  
 Most preclinical trials are carried out with males only due to a supposedly higher 
variability among females, not confirmed by data from our laboratory (Parra et al., 1999). 
This is a somewhat inappropriate policy given that women consume more psychotropic 
medication than men (Cafferata et al., 1983). Furthermore, there are important reasons for 
evaluating the impact of antidepressants on both male and female subjects:  
a. Gender differences in the epidemiology of depression, which is more common in 
women than in men (American Psychiatric Association, 1994; Kornstein, 1997). 
b. Gender differences in the efficacy of some antidepressants, such as maprotiline and 
fluoxetine (Martényi et al., 2001). 
c. Differences in pharmacokinetics and pharmacodynamics between men and women 
have been reported for several drugs, including antidepressants (Frackiewicz et al., 
2000; Gandhi et al., 2004). 
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